Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879012 | 0.93 | ALOX5AP (0.35) | ALOX5APPDE5AKCNH2HRH3 | |
| SCHEMBL4872012 | 0.92 | MDM2 (0.35) | ALOX5APMDM2FFAR4 | |
| SCHEMBL4873267 | 0.91 | ALOX5AP (0.34) | GRIN1GRIN2BALOX5APMDM2KMO | |
| SCHEMBL4875175 | 0.88 | ERCC5 (0.38) | ALOX5APPDE5AKCNH2 | |
| SCHEMBL4868085 | 0.88 | F10 (0.33) | ALOX5AP | |
| SCHEMBL4877200 | 0.86 | KDM4E (0.33) | ALOX5APKCNH2HRH3 | |
| SCHEMBL4867590 | 0.86 | ALOX5AP (0.35) | ALOX5APMDM2KMO | |
| SCHEMBL4872478 | 0.86 | KCNH2 (0.39) | MDM2KCNH2HRH3 | |
| SCHEMBL4876388 | 0.86 | ALOX5AP (0.38) | ALOX5APMDM2 | |
| SCHEMBL4866909 | 0.85 | ALOX5AP (0.35) | GRIN1GRIN2BALOX5APMDM2KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | GRIN1 2653/4885GRIN2B 3420/4885ALOX5AP 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.